key: cord-0810127-nzrr7kdn authors: Torres, Monique; Collins, Katherine; Corbit, Mariah; Ramirez, Maureen; Winters, Caroline Riley; Katz, Lily; Ross, Morgan; Relkin, Norman; Zhou, Wenli title: Comparison of Saliva and Nasopharyngeal Swab SARS-CoV-2 RT-qPCR Testing in a Community Setting date: 2020-11-17 journal: J Infect DOI: 10.1016/j.jinf.2020.11.015 sha: 320e7a6aba0489313e1c60f3bf1320a3fb188b40 doc_id: 810127 cord_uid: nzrr7kdn nan Several groups [1] [2] [3] [4] have reported that saliva specimens perform as well or better than nasopharyngeal swabs (NPS) in hospital, emergency care and mass screening settings when testing for SARS-CoV-2 with reverse transcriptase real time PCR (RT-qPCR). In contrast, others found saliva less sensitive than NPS in community 5 or mildly infected outpatient settings 6 . To better understand saliva's performance in the SARS-CoV-2 RT-qPCR assay, we collected paired NPS and saliva from self-reported mild symptomatic or asymptomatic individuals at two community testing sites in Tucson, Arizona between late July and early September 2020. The study was reviewed and approved by the Advarra Institutional Research Board. Self-collection of saliva was performed using either the SDNA-1000 Saliva Collection device (Spectrum Solutions LLC, USA) or a sterile dry 50-ml conical vial followed by NPS collection within 10 minutes by medical staff. All samples were processed within 12 hours of collection using the Beckman RNAdvance Viral XP Reagent kit and the CDC 2019 nCoV Real-Time RT-PCR Diagnostic Panel with One Step PrimerScript TM III RT-PCR Kit (Takara Bio Inc. Japan). Using this platform, the viral yield of saliva was comparable to that of NPS using contrived samples and serial dilution of positive saliva samples. A total of 943 pairs of samples were collected and tested, of which 108 pairs had positive results (11.5%). This included n=54 samples in which only NPS samples were positive ("NPS-only"), n=8 in which only saliva was positive ("saliva-only") and n=46 in which both NPS and saliva were positive ("double positive"). The overall positive agreement of saliva to NPS (saliva sensitivity) was 46% (95% CI: 36.6% -55.7%). The average saliva cycle threshold (Ct) value was 26.8+5.9 (N1, same for all below) which was significantly higher than 23.2+8.5 (paired t-test, p<10 -4 ) of NPS, consistent with several earlier reports 4-6 . Of 843 NPS negatives, 8 saliva specimens were positive. The saliva specificity relative to NPS was 99.1% (n=843, 95% CI: 98.1% to 99.5%) with an average Ct of 34.4+3.4. Saliva sensitivity varied inversely with NPS Ct. When NPS Ct was lower than 26, saliva was positive in all NPS positive samples (n=27, sensitivity 100%, 95% CI: 87.5%-100%). When NPS Ct was between 26 and 33, only 48.0% of the positive NPS samples had paired positive saliva (n=25, 95% CI: 30.0%-66.5%). When NPS Ct was greater than 33, the saliva sensitivity further decreased to 14.6% (n=48, 95% CI: 7.3% -27.2%) ( Figure 1 ). Although the lowest NPS Ct groups had a significantly higher number of symptomatic individuals (p=0.04, Figure 1 pie chart), the overall saliva sensitivity is not related to the symptoms (Table 1) . Among NPS-only positive individuals, a total of 22 had onset of symptoms 14 days earlier or SARS-COV-2 positivity longer than 14 days whereas there was only one such case among double positives. After excluding these individuals, the saliva sensitivity reached 86.7% (n=45, 95% CI: 73.8% -93.7%) for NPS Ct of 33 and lower ( Figure 1 ). Our results corroborate early reports that saliva positivity declines more rapidly than that of NPS after two weeks of infection 2,6 . We examined the effects of other factors on saliva sensitivity, including age, gender, race, saliva collection device, and collection site ( Table 1 ). The double positive group had a significant number of individuals younger than age 30 (p=0.003). Gender, race, and collection (Table 1) , the difference is significant (p=0.001). Moreover, of 3 NPS-only positives at Site 2, one was inconclusive on saliva testing and two were known positive for more than 14 days at the time of this study. The two sites generated two different results with saliva more sensitive at one site, and less at another. The differences cannot be readily attributed to procedural variations. The two collection sites had the same rotating medical staff, followed the same collection and transportation protocol, and collected the paired specimens on the same days. The samples from two sites were randomly batched together for the lab analysis. The population at Site 2 was more suburban and socially distanced with an average age of 47.8 years, compared to 34.4 years at Site 1. Since the performance of laboratory tests can vary as a function of the prevalence of the disease, the disparate results profiles across sites could be related to the differences in the SARS-CoV-2 positivity at the two testing sites. It is also possible that the observed differences were due to demographic differences or a chance occurrence. Nearly half (47%) of all NPS positives in our cohort had Ct higher than 33. Some had prolonged presence of the virus and other had unknown date of initial infection, likely a true picture of many communities. Most of those people were tested negative by saliva. Previous Because its collection is non-invasive and does not require trained medical staff, saliva is a desirable specimen for COVID-19 screening and diagnostics. Our results indicate that RT-qPCR testing of saliva in a community-based population can effectively identify infected individuals with the high viral loads in a timely fashion, which is important for identifying those who may have the greatest potential to spread the virus. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Tables Table 1 Demographic distribution of double positive, NPS- Saliva is a reliable tool to detect SARS-CoV-2 Comparison of SARS-CoV-2 detection in nasopharyngeal swab and saliva Saliva or Nasopharyngeal Swab Specimens for Detection of SARS-CoV-2 Mass screening of asymptomatic persons for SARS-CoV-2 using saliva Non-invasive saliva specimens for the diagnosis of COVID-19: caution in mild outpatient cohorts with low prevalence Saliva is less sensitive than nasopharyngeal swabs for COVID-19 detection in the community setting Predicting infectious SARS-CoV-2 from diagnostic samples Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19 Should qualitative RT-PCR be used to determine release from isolation of COVID-19 patients? False Negative Tests for SARS-CoV-2 Infection -Challenges and Implications We would like to thank Dr. Theresa Cullen and Pima County Health Department for their support in this study. We are also grateful to Dr. Carlos M. Perez-Velez (Pima County Health Department and University of Arizona College of Medicine) for discussing the testing issues and critically reviewing this manuscript, and Mr. Zhongxu Zhu for helping with Fisher exact test using R-software.